Talphera Announces $26 Million Capital Commitment Through a Combination of a Non-Dilutive Royalty Monetization and Equity Offering
Summary
"The combination of the non-dilutive and equity financing transactions is expected to secure our funding through a potential FDA approval of Niyad targeted for the first half of 2025," said Vince Angotti, Talphera Chief Executive Officer. "The strong support from Nantahala and Rosalind demonstrated by the capital committed further enforces our belief in Niyads market potential and the significance of the recent corporate rebranding to Talphera. We are eager to demonstrate through our pivotal study why Niyad has received Breakthrough Designation from the FDA, and potentially introduce a much-anticipated new alternative to healthcare providers," continued Angotti. To the degree financial information is included in this press release, it is in summary form only and must be considered in the context of the full details provided in Talphera s most recent annual, quarterly or current report as filed or furnished with the SEC. This is due to the inherent difficulty of forecasting the timing or amount non-cash stock-based compensation and other items that would impact the most directly comparable forward-looking U.S. GAAP financial measure that have not yet occurred and cannot be reasonably estimated.